Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
On a global scale, gastric adenocarcinoma (GCa) accounts for a large burden of death from cancer. Despite advances in systemic therapy and surgical technique, the fatality rate for GCa remains unacceptably high in Europe and North America, where diagnosis is typically made at an advanced stage. Biomarkers that can accurately predict response to new therapies and provide novel therapeutic strategies are urgently sought. FAM46C, a putative noncanonical nucleotidyltransferase, has garnered interest for its tumor suppressor function in multiple myeloma. A frequent and profound depletion of FAM46C has been described in GCa patients from China, Japan and now Canada. Furthermore, the degree of FAM46C depletion meaningfully portends cancer recurrence following resection, and death from GCa. In this review, we provide an updated summary of the literature regarding FAM46C as a biomarker in GCa and explore the potential mechanism(s) through which FAM46C depletion promotes GCa progression, including dis-inhibition of oncogenic Plk4 kinase activity. We highlight the potential for restoration of FAM46C levels as a therapeutic strategy. Norcantharidin, a synthetic analogue of the traditional Chinese medicine cantharidin derived from the blister beetle, is the only bio-available compound presently known to upregulate FAM46C expression and is under investigation in phase one trials in cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399874 | PMC |
| http://dx.doi.org/10.21037/jgo-24-105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FAM46C Expression Sensitizes Multiple Myeloma Cells to PF-543-Induced Cytotoxicity.
Biomolecules
April 2025
INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, 20122 Milan, Italy.
FAM46C is a tumor suppressor initially identified in multiple myeloma (MM) but increasingly recognized for its role also in other cancers. Despite its significance, studies exploring the therapeutic potential of FAM46C in combination with targeted treatments remain limited. Sphingosine kinases (SphK1 and SphK2) are key regulators of sphingolipid signaling, a pathway essential for maintaining cell structure and function but frequently deregulated in tumors, making them promising targets for cancer therapy.
View Article and Find Full Text PDFModulation of Autophagy by Oncosuppressor FAM46C and Its Implications for Cancer Therapy: An Intriguing Perspective.
Biomolecules
January 2025
INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, 20122 Milan, Italy.
Cancer is one of the major challenges in medicine, necessitating continuous advancements in therapeutic approaches. Autophagy, an intracellular pathway essential for cellular homeostasis and stress response, has emerged as a promising target for cancer treatment. In this context, FAM46C, a novel pan-cancer tumour suppressor, has been shown to induce apoptosis in multiple myeloma cells through indirect inhibition of autophagy.
View Article and Find Full Text PDFInduction of FAM46C expression mediated by DNMT3A downregulation is involved in early-onset preeclampsia through gene body methylation.
Cell Signal
January 2025
Clinical and Translational Research Center, Department of Obstetrics, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.. Ele
Article Synopsis
- - Aberrant DNA methylation, especially in the FAM46C gene, has been linked to preeclampsia, marking a potential mechanism not fully understood yet.
- - Research methods included global DNA methylation assessment and RNA-seq, revealing that knocking down DNMT3A increased methylation and FAM46C expression, affecting trophoblast cell migration and invasion.
- - The study concluded that increased FAM46C expression and its altered methylation pattern, driven by DNMT3A, play significant roles in the development of early-onset preeclampsia.
Genetic architecture of oral glucose-stimulated insulin release provides biological insights into type 2 diabetes aetiology.
Nat Metab
October 2024
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen (UCPH), Copenhagen, Denmark.
Article Synopsis
- The study explores the genetic factors influencing β-cell function (BCF) and their relationship to type 2 diabetes (T2D), expanding on previous genetic research using large-scale data.
- By analyzing GWAS data from around 26,000 individuals, the researchers identified 55 unique genetic associations related to BCF traits derived from oral glucose tolerance tests.
- The findings reveal key genes that regulate insulin secretion and illustrate how different genetic mechanisms can affect T2D risk, offering a deeper understanding of the complex biology behind the disease.
The emerging role of FAM46C as a biomarker and therapeutic target in gastric adenocarcinoma.
J Gastrointest Oncol
August 2024
Department of Surgery, University of Toronto, Toronto, Canada.
Article Synopsis
- Gastric adenocarcinoma (GCa) has a high fatality rate in Europe and North America, largely due to late-stage diagnoses, despite advancements in treatment options.
- There is significant interest in FAM46C, a protein linked to tumor suppression, as its depletion is commonly observed in GCa patients and is associated with cancer recurrence and mortality.
- Research is exploring FAM46C as a potential biomarker and therapeutic target for GCa progression, with Norcantharidin emerging as a promising compound to restore FAM46C levels currently in phase one clinical trials.